While the expression of SGLT2 is mainly restricted to the early proximal tubules of the kidney, interestingly, its expression has been detected in pancreas, prostate tumors, and glioblastoma, which opens the door to potential new strategies for cancer treatment by targeting SGLT2 in those tissues [202]. This evidence concerns the gene SLC5A2 and prostate neoplasm.